Wednesday, November 27, 2013 12:25:45 PM
Jeff Margolis
Vice-president,
Cortex Pharmaceuticals Inc.
126 Valley Road, Suite C
Glen Rock, New Jersey 07452
(917) 834-7206
jmargolis@cortexpharm.com
11/12/2013
Jeff,
I began investing in Cortex about a decade ago at the behest of my then stock broker, XXXXXXX, formerly of XXXXXXXXX here in XXXXX, Virginia. Although we both had experience in biotech investing, we hadn't previously considered the Neurological Pharma business as an avenue. We carried on a phone and email correspondence for many years with Dr. Stoll, and later Mark Varney. Based on their credentials and the novel action of ampakines my stock broker carved out a large position both with clients and personally. While my position was tiny, most of which I liquidated several years ago, I've held a small amount of several hundred thousand shares for no reason in particular other than in deference to my broker, whose love affair with Cortex has essentially cost him everything.
I was curious as to how your efforts in whittling down the debt run up by your predecessors might be progressing. It seems that if those issues could be put to rest, a new approach to the commercialization of ampakines might be pursued. The reason for my renewed concern about the fate of our technology is that my father lost his three year battle with Dementia on September the 11th of this year. Despite our family's medical background (Dentistry and Neurosurgery), it seemed no treatment could even slow down the progress of his decline.
Perhaps the future of this technology lies as a dietary supplement, thus avoiding the pit dug by previous managements attempts to gain FDA approval, and the non-interest of Big Pharma in our platform.
I'm sure you are exploring all options at this juncture, but would appreciate any update you might consider providing me that wouldn't alarm your legal department.
Sincerely,
XXXXXXXXXXXXX
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:05:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 12:52:24 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM